91Ö±²¥

All publications

Journal articles

• Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R & Khwaja A (2021) . Bone, 143, 115699-115699.
• Salam S, Gallagher O, Hughes D, Khwaja A & Eastell R (2020) . Bone.
• Salam S, Gallagher O, Gossiel F, Khwaja A & Eastell R (2020) . Bone Reports, 13, 100670-100670.
• Salam S, Gallagher O, Gossiel F, Khwaja A & Eastell R (2020) . Nephrology Dialysis Transplantation, 35(Supplement_3).
• Esapa CT, Piret SE, Nesbit MA, Thomas GP, Coulton LA, Gallagher OM, Simon MM, Kumar S, Mallon A-M, Bellantuono I , Brown MA et al (2018) . JBMR Plus, 2(3), 154-163.
• Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A & Eastell R (2018) . Journal of the American Society of Nephrology, 29(5), 1557-1565.
• Besio R, Maruelli S, Gioia R, Villa I, Grabowski P, Gallagher O, Bishop NJ, Foster S, De Lorenzi E, Colombo R , Diaz JLD et al (2015) . Bone, 72, 53-64.
• Foster S, Forestier-Zhang L, Grabowski P, Gallagher O, Madan S, Arundel P & Bishop N (2014) . Annals of Medicine and Surgery, 3(2), 49-50.
• Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, Ebetino FH, Kassem M & Heegaard A-M (2009) . Int J Cancer, 125(5), 1177-1185.
• Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Vanderkerken K, Seehra JS & Croucher PI (2008) RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone disease in multiple myeloma. CLIN EXP METASTAS, 25, 64-64.
• Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K , Van Camp B et al (2007) . Int J Cancer, 121(8), 1857-1861.
• Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Glassford J, Otsuki T, Nathwani AC , Croucher PI et al (2007) . Leukemia, 21(10), 2181-2191.
• Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher PI (2007) . Cancer Res, 67(1), 202-208.
• Rabin N, Kyriakou C, Benjamin R, Pizzey A, Gallagher O, Singh N, Buckle C, Croucher P, Nathwani A & Yong K (2006) . Blood, 108(11), 505-505.

Conference proceedings papers

• Salam S, Gallagher O, Hughes D, Khwaja A & Eastell R (2021) . Bone Reports, Vol. 14(Supplement). Digital Congress, 6 May 2021 - 8 May 2021.
• Salam S, Paggiosi M, Gallagher O, Eastell R & Khwaja A (2019) . Nephrology Dialysis Transplantation, Vol. 34(Supplement_1). Budapest, Hungary, 13 June 2019 - 16 June 2019.
• Salam S, Paggiosi M, Gallagher O, Eastell R & Khwaja A (2019) VASCULAR CALCIFICATION IN ADVANCED CKD AND ITS RELATIONSHIP WITH BONE MICROSTRUCTURES. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34
• Foster S, Grabowski PS, Gallagher O, Besio R, Rossi A, Bishop N & Forlino A (2013) Prolidase deficient mice are osteoporotic in early life. Bone Abstracts, Vol. 2 (pp OC22-OC22)
• Forestier-Zhang L, Grabowski PS, Gallagher O, Patel A, Madan S, Arundel P & Bishop N (2013) Assessing bone quality and fracture resistance in children using microindentation. Bone Abstracts, Vol. 2 (pp P86-P86)
• Chantry AD, Baud'huin M, Coulton L, Gallagher O, Evans H, Lath D, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher PI (2011) Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 7-7)
• Williams A, Lawson M, Bos T, Amani E, Hough J, Evans H, Lath D, Gallagher O, Coulton L, Vanderkerken K & Croucher P (2010) . BONE, Vol. 47 (pp S328-S328)
• Chantry A, Coulton L, Gallagher O, Evans H, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher R (2009) . BONE, Vol. 44 (pp S55-S55)
• Chantry AD, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1118-1118)
• Rabin N, Coulton L, Gallagher OM, Benjamin R, Singh N, McIntosh JH, Buckle C, Nathwani A, Croucher P & Yong K (2007) Micro-computer tomography (MICROCT) analysis demonstrates extensive bone loss in the KMS-12-BM xenogeneic murine model of myeloma. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 136-136)
• Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 133-133)
• Rabin N, Kyriakou C, Benjamin R, Pizzey A, Gallagher O, Singh N, Buckle C, Croucher P, Nathwani A & Yong K (2006) Gene modified human mesenchymal stem cells expressing osteoprotegerin inhibit osteoclast activation and increase trabecular bone area in a xenogeneic murine model of myeloma.. BLOOD, Vol. 108(11) (pp 153A-153A)
• Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher P (2006) An osteoprotegerin-like peptidomimetic (OP3-4) inhibits osteoclastic bone resorption and osteolytic bone disease in multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S82-S82)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S137-S137)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
• Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher PI (2006) An osteoprotegerin-like peptidomimetic (OP3-4) inhibits osteoclastic bone resorption and osteolytic bone disease in multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1151-1151)
• Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher P (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 32 (pp S35-S35)
• Kartsogiannis V, Ly C, Zhou H, Gallagher O, Buckle C, De Leenheer E, Vanderkerken K, Ng KN, Martin TJ, Gillespie MT & Croucher PI (2005) Expression of RANKL, OPG, PTHrP and OCIL in multiple myeloma are influenced by the tumor cells' proximity to bone.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S211-S211)
• Kartsogiannis V, Ly C, Zhou H, Gallagher O, De Leenhey E, Buckle C, Ng KW, Martin TJ, Gillespie MT & Croucher P (2005) Expression of PTHrP, RANK, OPG and OCIL in multiple myeloma are influenced by the tumor cells' proximity to bone. CANCER TREATMENT REVIEWS, Vol. 31 (pp S25-S25)
• Roberts SA, Gallagher O, Jones RD, English KM, Jones TH & Channer KS (2002) Quantification of lumen occlusion due to neointimal cell growth in cultured thoracic aortae from testicular feminized and control mice. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 137
• Forestier-Zhang LY, Patel A, Gallagher OM, Grabowski P, Madan S, Arundel P & Bishop NJ () Direct fracture resistance testing of bone in infants and children. Medical School Research Day. University of 91Ö±²¥, 11 June 2012 - 12 June 2012.